About the Company
Moderna, Inc. ( mə-DUR-nə) is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's only commercial product is the Moderna COVID-19 vaccine, marketed as Spikevax. The company has 45 treatment and vaccine candidates, of which 38 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, respiratory syncytial virus, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. The company's pipeline also includes a cell therapy-based treatment: a relaxin fusion protein being developed to treat acute decompensated heart failure. It also includes candidates that use OX40 ligand, interleukin 23, IL36G, and interleukin 12 for cancer immunotherapy, specifically treatment of breast cancer, urothelial carcinoma, lymphoma, and melanoma. Also being developed by Moderna is a regenerative medicine treatment that encodes vascular endothelial growth factor A to stimulate blood vessel growth for patients with myocardial ischemia.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MRNA News
Should You Buy Moderna Before May 12?
The U.S. Food and Drug Administration (FDA) is set to issue a decision on the company's respiratory syncytial virus (RSV) ...
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including ...
Moderna Employees Should Use ChatGPT at Least 20 Times a Day, CEO Says
Moderna and OpenAI announced an ongoing partnership Wednesday to embed AI across Moderna’s business, giving its teams — ...
Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?
Moderna Inc (NASDAQ:MRNA) shares are trading higher Wednesday after the company announced an ongoing collaboration with ...
Moderna Investors Should Beware Patent-Dispute Fallout
Moderna's stock soared on positive cancer vaccine trial results, but legal troubles loom as a patent dispute threatens ...
Moderna stock closes in green after eight sessions of losses
Maddie Meyer/Getty Images News Moderna (NASDAQ:MRNA) closed in green and snapped an eight-day losing streak after having lost ...
At Moderna, OpenAI’s GPTs Are Changing Almost Everything
People literally talk about how AI is going to cure diseases someday, and I think this is a very meaningful first step,” said ...
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Generative AI will help advance Moderna’s broad and diverse portfolio to maximize the Company’s impact on patients ...
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the ...
Moderna turns to AI to change how its employees work
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines ...
Moderna gets grant for vaccine composition for varicella zoster virus
Discover how Moderna's groundbreaking patent for a nucleic acid vaccine targeting varicella zoster virus could revolutionize immunization. Learn about the innovative mRNA and lipid nanoparticle ...
Loading the latest forecasts...